In particular, we studied PSMA‐positive PC3‐PIP prostate cancer tumors in vivo, which proved to be particularly heterogeneous in their morphology (as shown in Figure S11), and we demonstrated that the same total α‐particle radioactivity delivered by any combinations of the two carriers (the liposomes and a PSMA‐targeting antibody) improved overall efficacy (i.e., tumor growth inhibition). Here, FOLH1 is linked to prostate carcinoma.